Serum levels of antibodies against paraoxonase 1 and high-density lipoprotein are potential early biomarkers of endothelial damage and premature atherosclerosis in SLE, and thus they are useful therapeutic targets for preventing CVD in SLE patients [84]. Here, PON1 is linked to systemic lupus erythematosus.